LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15.
Further randomized controlled trials are required to assess the efficacy and safety of LDN therapy in active Crohn's disease in both adults and children.Cochrane Database Syst Rev. 2014 Feb 21;2:CD010410. doi: 10.1002/14651858.CD010410.pub2.
The preliminary evidence continues to show that low-dose naltrexone has a specific and clinically beneficial impact on fibromyalgia pain. The medication is widely available, inexpensive, safe, and well-tolerated. Parallel-group randomized controlled trials are needed to fully determine the efficacy of the medication.Arthritis Rheum. 2013 Feb;65(2):529-38. doi: 10.1002/art.37734.
We conclude that low-dose naltrexone may be an effective, highly tolerable, and inexpensive treatment for fibromyalgia.Pain Med. 2009 May-Jun;10(4):663-72. doi: 10.1111/j.1526-4637.2009.00613.x. Epub 2009 Apr 22.
Complex Regional Pain Syndrome (CRPS)
Prominent CRPS symptoms remitted in these two patients, including dystonic spasms and fixed dystonia (respectively), following treatment with low-dose naltrexone (LDN).J Neuroimmune Pharmacol. 2013 Jun;8(3):470-6. doi: 10.1007/s11481-013-9451-y. Epub 2013 Apr 2.
Naltrexone therapy seems safe with limited toxicity when given to children with Crohn's disease and may reduce disease activity.J Clin Gastroenterol. 2013 Apr;47(4):339-45. doi: 10.1097/MCG.0b013e3182702f2b.
Naltrexone improves clinical and inflammatory activity of subjects with moderate to severe Crohn's disease compared to placebo-treated controls. Strategies to alter the endogenous opioid system provide promise for the treatment of Crohn's disease.Dig Dis Sci. 2011 Jul;56(7):2088-97. doi: 10.1007/s10620-011-1653-7. Epub 2011 Mar 8.
Eighty-nine percent of patients exhibited a response to therapy and 67% achieved a remission (P < 0.001). LDN therapy appears effective and safe in subjects with active Crohn's disease. Further studies are needed to explore the use of this compound.Am J Gastroenterol. 2007 Apr;102(4):820-8. Epub 2007 Jan 11.
LDN significantly improved mental health quality of life indices. Further studies with LDN in MS are warranted.Ann Neurol. 2010 Aug;68(2):145-50. doi: 10.1002/ana.22006.
Our data clearly indicate that LDN is safe and well tolerated in patients with PPMS (primary progressive multiple sclerosis).Mult Scler. 2008 Sep;14(8):1076-83. doi: 10.1177/1352458508095828.
Irritable Bowel Syndrome
PTI-901 (low-dose NTX) improves pain and overall feeling, and is well tolerated by IBS patients. A large, randomized, double-blind, placebo-controlled study is justified.Dig Dis Sci. 2006 Dec;51(12):2128-33. Epub 2006 Nov 1.
Thus, the common denominator of intermittent opioid receptor blockade by short-term NTX or LDN on ovarian cancer proliferation and tumorigenesis recorded herein appears to be related to the OGF-OGFr axis. These preclinical data may offer a non-toxic and efficacious pathway-related treatment that can benefit patients with ovarian cancer.Exp Biol Med (Maywood). 2011 Jul;236(7):883-95. doi: 10.1258/ebm.2011.011096. Epub 2011 Jun 17.
This study shows that a native opioid pathway can suppress human ovarian cancer in a xenograft model, and provides novel non-toxic therapies for the treatment of this lethal neoplasia.Gynecol Oncol. 2011 Aug;122(2):382-8. doi: 10.1016/j.ygyno.2011.04.009. Epub 2011 Apr 30.